Payment overview · 2025
General Payments
$745.02
38 reported records · 12 companies
Healthcare provider profile · identity verified
Stephen E Carney, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · VAN BUREN, AR · NPI 1609815877
Verified facts
What the public records show
CMS Open Payments records show Stephen E Carney, M.D. received $745.02 in general payments during 2025 across 38 reported records.
AstraZeneca Pharmaceuticals LP accounted for 28.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $211.12 | 28.3% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $144.37 | 19.4% | 13 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $86.97 | 11.7% | 4 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $86.93 | 11.7% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $39.03 | 5.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.14 | 4.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.56 | 4.2% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.00 | 3.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.94 | 3.1% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $22.85 | 3.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.54 | 2.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.57 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $745.02 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $144.37 | 13 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $120.89 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $90.23 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $86.97 | 4 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $86.93 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $54.77 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $39.03 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $34.14 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $31.56 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.94 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $22.85 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.54 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
60 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
37 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 938 | 123 |
| Gabapentin | Gabapentin | 708 | 123 |
| Atorvastatin Calcium | Atorvastatin Calcium | 590 | 136 |
| Amlodipine Besylate | Amlodipine Besylate | 449 | 107 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 408 | 89 |
| Lisinopril | Lisinopril | 404 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 390 | 75 |
| Omeprazole | Omeprazole | 380 | 94 |
| Tizanidine Hcl | Tizanidine Hcl | 371 | 70 |
| Alprazolam | Alprazolam | 365 | 56 |
| Metformin Hcl | Metformin Hcl | 305 | 76 |
| Trazodone Hcl | Trazodone Hcl | 282 | 55 |
| Clonazepam | Clonazepam | 281 | 39 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 276 | 60 |
| Furosemide | Furosemide | 248 | 59 |
| Meloxicam | Meloxicam | 234 | 48 |
| Buspirone Hcl | Buspirone Hcl | 217 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 206 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 185 | 38 |
| Tramadol Hcl | Tramadol Hcl | 174 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 160 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 158 | 43 |
| Losartan Potassium | Losartan Potassium | 156 | 31 |
| Azithromycin | Azithromycin | 153 | 87 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 151 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 147 | 33 |
| Potassium Chloride | Potassium Chloride | 145 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 144 | 23 |
| Estradiol | Estradiol | 135 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 128 | 27 |
| Sertraline Hcl | Sertraline Hcl | 127 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 123 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 117 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 114 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 114 | 29 |
| Simvastatin | Simvastatin | 113 | 28 |
| Carvedilol | Carvedilol | 110 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 107 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 107 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 105 | 24 |
| Ondansetron Odt | Ondansetron | 98 | 23 |
| Promethazine Hcl | Promethazine Hcl | 96 | 20 |
| Ventolin Hfa | Albuterol Sulfate | 96 | 24 |
| Diazepam | Diazepam | 92 | 11 |
| Pregabalin | Pregabalin | 90 | 21 |
| Aripiprazole | Aripiprazole | 80 | 16 |
| Ibuprofen | Ibuprofen | 80 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 78 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 77 | 20 |
| Allopurinol | Allopurinol | 75 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 21 |
| Eliquis | Apixaban | 69 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 69 | 12 |
| Lorazepam | Lorazepam | 68 | suppressed |
| Ozempic | Semaglutide | 68 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 68 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 66 | suppressed |
| Mirtazapine | Mirtazapine | 65 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 16 |
| Naproxen | Naproxen | 63 | 20 |
| Alendronate Sodium | Alendronate Sodium | 60 | 13 |
| Linzess | Linaclotide | 60 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 15 |
| Glipizide | Glipizide | 56 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 55 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 55 | 36 |
| Montelukast Sodium | Montelukast Sodium | 53 | 13 |
| Clonidine Hcl | Clonidine Hcl | 52 | suppressed |
| Levetiracetam | Levetiracetam | 50 | suppressed |
| Topiramate | Topiramate | 49 | suppressed |
| Celecoxib | Celecoxib | 47 | 13 |
| Atenolol | Atenolol | 46 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 46 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 45 | suppressed |
| Baclofen | Baclofen | 44 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 44 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | suppressed |
| Methylprednisolone | Methylprednisolone | 42 | 29 |
| Breo Ellipta | Fluticasone/Vilanterol | 41 | suppressed |
| Methocarbamol | Methocarbamol | 37 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | 12 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 36 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 35 | 14 |
| Temazepam | Temazepam | 35 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 32 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 32 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Prednisone | Prednisone | 26 | suppressed |
| Zaleplon | Zaleplon | 26 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Risperidone | Risperidone | 25 | suppressed |
| Cefadroxil | Cefadroxil | 24 | 19 |
| Levofloxacin | Levofloxacin | 24 | 18 |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 14 |
| Oxcarbazepine | Oxcarbazepine | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | suppressed |
| Vraylar | Cariprazine Hcl | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 19 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Carbamazepine Er | Carbamazepine | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 16 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Glyburide | Glyburide | 15 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Klor-Con M10 | Potassium Chloride | 12 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Olanzapine Odt | Olanzapine | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $745.02 · 38 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, FANAPT, FARXIGA, GEMTESA, JOURNAVX, LEQVIO, TRELEGY ELLIPTA, VRAYLAR, Veozah, XIFAXAN, XYOSTED | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error